Gemcitabine vs. GEMOX (gemcitabine + oxaliplatin) in non-resectable pancreatic adenocarcinoma: Interim results of GERCOR/GISCAD intergroup Phase III

Reviewer: Tracy d'Entremont, MD
OncoLink
Ultima Vez Modificado: 2 de junio del 2003

Translation for this article does not exist